INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
EClinicalMedicine
December 2020
Nature Communications
May 2020
The New England Journal of Medicine
October 2017
The Lancet Infectious Diseases
July 2019
The Journal of Infectious Diseases
March 2019
| Title | Disease Target | Product |
|---|---|---|
| Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017 | hTERT | INO-5401 |
| Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013 | hTERT | INO-5401 |
| A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017 | WT1 | INO-5401 |
| CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020 | PSA | INO-5151 |
| Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011 | PSA, PSMA | INO-5401 |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2021 INOVIO Pharmaceuticals. All rights reserved.
